Personalized treatment for glioblastoma using patient-derived drug screening
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial (ATTRACT)
This study is testing if creating personalized treatment plans using patients' own cancer cells can help people with glioblastoma get better results than standard treatment alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Vienna, State of Vienna) |
| Trial ID | NCT06512311 on ClinicalTrials.gov |
What this trial studies
This clinical trial utilizes patient-derived cell line (PDC) drug screening to create personalized treatment plans for individuals diagnosed with glioblastoma. Participants will be randomized into two groups: one receiving standard histology analysis alongside PDC-based drug screening, and the other receiving only standard histology analysis. The outcomes of both groups will be compared to assess the effectiveness of the personalized approach. The study aims to improve treatment strategies by tailoring therapies based on individual patient responses to drugs.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with newly diagnosed IDH wildtype glioblastoma and available tissue for drug screening.
Not a fit: Patients currently participating in other therapeutic clinical trials or with concurrent malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for glioblastoma patients.
How similar studies have performed: Previous studies utilizing personalized medicine approaches in cancer treatment have shown promising results, indicating potential success for this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-75 * ECOG performance status 0-2 * Newly diagnosed glioblastoma, IDH wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System * MGMT promotor unmethylated per local investigator * Tissue available for drug screening (successful PDC establishment from surgical material) * Scheduled for concomitant radio-chemotherapy with temozolomide * Written informed consent Exclusion Criteria: * Current participation in another therapeutic clinical trial * Patients with a concurrent malignancy or malignancy within five years prior of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years * Pregnant or lactating women * Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody \[HBsAg\] test and a positive anti-hepatitis B core antibody \[HBcAb\] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. * Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥350 cells/mm3 , no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. * Any of the following co-morbidities: * Pre-existing severe peripheral neuropathy (\> CTCAE grade 2) * Hepatic impairment (Bilirubin Level \>1.5x-3x ULN) * Kidney dysfunction (CrCl \< 59 mL/min) * Cardiac dysfunction with left ventricular ejection fraction \<60 % * Any grade of interstitial lung disease * Ongoing or previous history of rhabdomyolysis * Acute pancreatitis * QTcF ≥480 msec * Diabetes mellitus with fasting glucose \> 250mg/dl or 13.9 mmol/L * Participants who are unable or unwilling to comply with the requirements of the protocol as assessed by the investigator.
Where this trial is running
Vienna, State of Vienna
- AKH Vienna, Department for Internal Medicine I, Oncology — Vienna, State of Vienna, Austria (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.